Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Number of End-users, Sales Volume & ASP by Product Type The global continuous glucose monitoring devices market will witness a robust CAGR of 11.5%, valued at $6.13 billion in 2021, expected to appreciate and reach $16.33 billion by 2030, confirms Strategic Market Research. The market for continuous glucose monitoring was dominated by North America in 2020, with a market share of over 35%. One of the latest technical innovations in managing diabetes is CGM (continuous glucose monitoring). In case of CGM, a biosensor, a sort of glucose-monitoring device is inserted into the body of the subject via a transcutaneous or subcutaneous method. The embedded sensor detects glucose levels in the blood or interstitial fluid and transfers the data via a type of transmitter to a monitor/receiver to show the findings. Due to their numerous advantages over traditional glucose monitoring devices, these systems are crucial in managing diabetes. Unlike traditional glucose monitors, these gadgets provide routine glucose monitoring, which is important for avoiding complications related to diabetes. Additionally, CGMS based technology has provided a blueprint for the closed loop bionic/artificial pancreas. Thus, companies producing glucose monitoring devices primarily focus on developing unique and cutting-edge CGMS. For healthcare settings (hospital ICUs, diagnostic centres & clinics), all age groups & geographic regions, it offers variety of uses. As a result, manufacturers of insulin pumps and glucose monitor patches have a lot of potential in the market for continuous glucose monitoring devices. The continuous glucose monitoring (CGM) device market is also driven by new product introductions, government initiatives, and rising awareness of diabetes preventative care. An additional element causing the increase in demand for continuous-glucose monitoring devices during COVID-19 outbreak is the government agencies' relaxing limitations along with the publication of guidelines for employing home use glucose metres as well as Continuous-Glucose Monitors in the hospital settings. Dexcom G6 & Abbott Free-Style Libre are two CGMs permitted for hospital usage. This was done primarily to ensure patient self-testing and the safety of medical personnel. The American Diabetes Association also released several online resources regarding diabetes and the effect of COVID-19 on diabetic patients. Furthermore, the pandemic has increased the necessity to examine the viability of Continuous Glucose Monitors in institutions to constantly monitor diabetic patients. The U.S. FDA published an advice in April 2020 to increase the accessibility of remote-monitoring devices, particularly CGMs, across all healthcare institutions in the U.S. due to the rising demand. Additionally, a lot of medical institutions and industry participants took significant action to meet the unmet needs of diabetic patients who were struggling financially during the pandemic. The American Diabetes Association, Insulin for Life, as well as the Diabetes Disaster Coalition, for instance, teamed together with Abbott in May 2020 to send 25,000 CGM sensors to hospitals throughout the United States. With such a sensor, these devices enable the observation of blood glucose over a range of time intervals, and the readings are relayed through a wireless network. The appropriate readings are then entered into diabetes management software to aid patients in better understanding of their condition. Key Industry Drivers - Increased Diabetes Prevalence likely to increase the demand for Continuous Glucose Monitoring Devices, Increased use of the CGM device in Different Market Segments to Promote growth The rising diabetes prevalence is primarily caused by several reasons, including rapid urbanization and the rising trend toward a sedentary lifestyle in emerging and developed nations. For instance, the International Diabetes Federation reported that in 2021, there were an expected 537 million adults worldwide who had diabetes, with China, India, the United States, Brazil, and Mexico making up an estimated 51.6% of those individuals. The prevalence of type-1 or insulin-dependent Type-2 diabetes patients has also significantly increased, which has contributed to the rapid global adoption of these monitoring systems. For instance, the International Diabetes Federation stated that in 2021, the rate of occurence of type 1 diabetes was anticipated to be 149.5 per 1,000 children and among adolescents it was between 0 to 19 years of age. Moreover, there is a growing demand for diabetes monitoring devices like CGMs due to the existence of a substantial patient population with insulin-dependent diabetes, the advent of new products by industry players, and favourable reimbursement policies. The continuous glucose monitoring devices market has been expected to expand between 2021 and 2030 due to the above mentioned robust factors. Real-time monitoring for patients who are insulin-dependent or rather patients with Type-2 diabetes is now possible because of the advent of cutting-edge technology like CGM systems by market players. Additionally, compared to SMBG (Self-Monitoring Blood Glucose) systems, CGM systems have a number of benefits, including being less intrusive, comfortable, providing real-time monitoring, and providing quick and accurate data. As a result, these unique advantages play a significant role in changing the perspective of patients' along with healthcare professionals in the favour of CGM. Moreover, due to these advantages CGM devices are utilized in different market segment which acts as a robust factor for the growth of this market throughout the forecasted period. For instance, as per data released by Abbott, there were 4 million FreeStyle Libre users worldwide in 2021 compared to 3 million in 2020. Thus the increase in the use of continuous glucose monitoring devices in various fields will promote growth throughout this anticipated time frame. Restraints - Reduced Rate of Diagnosis of Diabetes & Treatment in Emerging Economies to Limit the growth. One of the main causes of the lower adoption of continuous glucose monitoring systems, particularly in emerging nations, is the existence of a sizable segment of the population with undiagnosed diabetes. Compared to wealthy nations, countries like China, India, South Africa, Brazil, and others have a higher prevalence of delayed analysis and diagnosis due to the general public's ignorance of chronic illnesses like diabetes-mellitus. Additionally, the lack of modern and advanced procedures by public or private organizations and the restricted access to modern healthcare infrastructure may impede growth. According to a report from the IDF (International Diabetes Federation) published in 2021, it was found that nearly one in two diabetic patients lives in Africa, and 55.0 percent of people with diabetes in the APAC region do not have a diagnosis. The lower diagnosis and treatment rates are therefore primarily caused by all of the reasons mentioned above, which would consequently restrict the use of these systems in developing nations. Opportunities - Covid-19 To Positively Impact the Market, Routine Monitoring of Blood Glucose Levels Will Act as An Opportunity for The Market. COVID-19 is expected to benefit the growth of the market for continuous glucose monitoring devices because the virus has been discovered to be detrimental for diabetic individuals. The American Diabetes Association states that there is currently inadequate evidence to determine if people with diabetes are more prone to contract COVID-19 but such people can experience worse outcomes, such as increased rates of major complications. Therefore, continuous glucose monitoring of diabetic patients can help to identify early COVID-19 symptoms and help to determine the best course of treatment. A greater CAGR is anticipated during the projected period for the continuous glucose monitoring system (CGM) segment, due to their ability to routinely monitor the patient's blood glucose level. CGMs are becoming increasingly popular in both developed & developing nations, which is leading to the enormous expansion of this market sector and the use of this technology in different market segments. For instance, a 2021 article by John Wiley & Sons, Inc. noted that CGM systems were proven more effective than SMBG in controlling diabetes because of their simplicity of use, speed of results, and minimally invasive approach. Market Analysis Of Different Segments Covered in the Report Based on Component Integrated Insulin Pumps Sensors Receivers Transmitters Based on Product SMBG Systems (Testing Strips, Blood Glucose Meters, Lancets) CBM Systems (Transmitters, Sensors, Receiver) Based on Demographics Child Population (≤14 years) Adult population (>14 years) Based on Testing Site Alternate Site Testing Fingertip Testing Based on End User ICUs Diagnostics/Clinics Home Healthcare Based on Application, Gestational Diabetes Type 2 Diabetes Type 1 Diabetes Regional Coverage Analysis North America United States Mexico Canada Europe United Kingdom Deutschland France Spain Italy Netherlands Norway Sweden Denmark Finland Rest of Europe Asia-Pacific China Australia Japan South Korea India Rest of Asia-Pacific LAMEA Brazil Venezuela South Africa Argentina Saudi Arab Rest of LAMEA Component Analysis & Insights According to component, CGM device is divided into three main groups: transmitters, sensors & receivers. From research, it can be concluded that in 2020, the sensors market segment held the largest revenue share, with over 39% of the total revenue. Additionally, from 2021 to 2030, this segment is anticipated to have the quickest CAGR. The most complex component of the CGM device, the sensors are made of a metal filament which is even thinner than a needle and is inserted inside the fatty-layer of the human body, immediately beneath the skin. The technology utilized in transmitters/receivers is a bit different from that of a sensor. In the sensor, platinum gets combined with glucose oxidase to produce and generate hydrogen peroxidase, generating an electrical signal for the transmitter. The findings are shown on the device monitor by the receiver. Signals from the side of transmitter are received by a small, battery-operated receiver that shows the outcomes. The receiver shows a variety of graphs & statistics which can be utilized to modify medicine, which is advantageous for those who suffer from hypoglycemia or hyperglycemic disorders. Demographics Analysis & Insights Based on the Demographic segment, the continuous glucose monitoring devices market is divided into adults who are (>14 years) and children below (<14 years). The sector of the adult population (>14 years) is anticipated to grow at the fastest rate during the forecast period. This is explained by the fact that CGMs are regarded as an ideal instrument for managing diabetes in the adult population because it is a "ready-to-go" treatment, very efficient at managing diabetes, and a cost-effective system for working class/employed people, leading to its widespread acceptance by this age group. According to a US survey, 38% of the 23,000 adults and children diagnosed with type 1 diabetes used CGM in 2019, with the majority of users being between the ages of 26 and 50. Application Analysis & Insights By Application, the market has been divided into Gestational Diabetes, Type-2 diabetes & Type-1 diabetes. In 2021, the Type-2 diabetes market segment held a disproportionately large portion of the worldwide market share, driven by the prevalence of Type-2 diabetes patients who are insulin-dependent. For instance, the IDF (International Diabetes Federation) forecasted that there were approximately 537 million type-2 diabetics patient worldwide in 2021, with one in ten of the diabetic patient group at risk of developing this disease. In addition, the CGM is expected to be used more frequently in the type 1 diabetes segment due to its clinically demonstrated effectiveness in lowering the risk of hypoglycemia in this population. End-User Analysis & Insights Based on End-user, with a revenue share of more than 43% in 2020, the home care segment dominated the worldwide market. During the anticipated years, the sector will continue to grow at a rapid CAGR. The market has been segmented into home care, other end uses, and hospitals. From 2021 to 2030, the hospital category is anticipated to increase at 2nd highest CAGR of nearly 10 percent. The use of the CGM device in hospitals and other healthcare facilities in order to monitor blood-sugar level of patients diagnosed with diabetes-mellitus is one of the factors fuelling this expansion. According to clinical studies as published by NCBI, for individuals suffering with gestational diabetes-mellitus, CGM systems beat SMBG/Self monitoring Blood Glucose devices in terms of advantages.The advent of highly advanced diabetes treatment devices will further increase product acceptance in the hospital sector. Regional Analysis & Insights North America dominated the worldwide market for CGM devices based on region, with a sale percentage of more than 39% in 2020. Due to a well-established healthcare sector in the region, the local market will continue to grow at a consistent CAGR between 2021 to 2030, thereby maintaining its dominance. The regional market is also anticipated and poised to be driven by the increasing obesity cases, effective reimbursement regulations, and expanding public awareness of cutting-edge technologies for diabetes control. Conversely, from 2021 to 2030, APAC is anticipated to experience the quickest growth rate. The Asia-Pacific region is experiencing an increase in diabetic patients compared to other regions globally. India & China have the most diabetic patients across the globe, according to IDF (International Diabetes Federation). Type I & Type II diabetes have become very common due to the rising socioeconomic inequality & the rise in obesity cases. Continuous Glucose Monitoring Devices Market Report Coverage Report Attribute Details Forecast Period 2021 – 2030 Market size value in 2021 USD 6.13 Billion The Revenue forecast in 2030 USD 16.33 Billion Growth rate 11.5% The base year for estimation 2021 Historical data 2017 - 2021 Segments covered Components, Demographics, End-user, Region Regional scope Europe, Asia Pacific, North America, LAMEA Country scope US, Canada, Mexico, Germany, UK, France, Spain, Italy, Netherlands, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Africa, Brazil, Argentina, Venezuela, Saudi Arabia, South Africa, rest of LAMEA. Key companies profiled GlySens Incorporated, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Dexcom, Inc., Senseonics Holdings, Inc., A. Menarini Diagnostics, Medtronic plc, lifeScan IP Holdings, Echo Therapeutics, Inc., Johnson & Johnson, B Braun Melsungen AG, Terumo Corporation Continuous Glucose Monitoring Devices Market Competitive landscape Analysis Numerous multinational and local businesses are well represented in the market. Most top corporations engage in strategic partnerships, product development, merger & acquisition, & geographical expansion to enhance their market revenue share. For instance, Medtronic announced on November 2020 that the FDA had approved the "InPen," a smart-insulin pen designed for diabetic patients who require multiple daily injections. A Guardian-CGM system that allows for real time access to patient insulin and glucose data is included with the device. The following are the major companies in the market for continuous glucose monitoring devices: GlySens Incorporated Abbott Laboratories F. Hoffmann-La Roche Ltd. Dexcom, Inc. Senseonics Holdings, Inc. A. Menarini Diagnostics LifeScan IP Holdings LLC Medtronic plc Echo Therapeutics, Inc. Johnson & Johnson B Braun Melsungen AG Terumo Corporation Recent Developments As a pioneer in at-home testing solutions, EMPOWER CLINICS INC, on July 2022, introduced the Empower Blood Glucose Monitor. Empower Blood Glucose Monitor is a tiny medical gadget that gauges how much glucose is in the blood of an individual. Senseonics Holdings Inc, a company involved with medical technologies, specializing in the design and production of implantable, long-term CGM systems for diabetic people announced on June 2022 that the next-generation Eversense E3 continuous glucose monitoring system, the most durable system currently in the market with exceptional accuracy, has been given CE Mark approval. The Eversense E3 can now be sold in member states of the European Union (E.U.). In Illinois, more than 1.3 million people have diabetes, and they must monitor their blood-sugar levels throughout the day. On June 2022, a bill was passed which makes it easier for people to access continuous glucose monitors. By January 2024, the new bill mandates that health plans or health insurance must include continuous glucose monitors (CGM) for diabetic patients. On June 2022, Abbott revealed that it is working on a novel bio wearable device that will combine a sensor to continually monitor glucose and ketone levels. The system has received the U.S. Food and Drug Administration's breakthrough device designation. The sensor which can detect glucose-ketone will share the same dimensions as Abbott's Free-Style Libre 3 sensor, which is the smallest & thinnest continuous glucose monitoring sensor in the world. It will also be connected to Abbott's digital ecosystem, which includes mobile apps for patients and caregivers as well as cloud-based data management software for remote monitoring by medical professionals. In March 2021, the Accu-Chek Instant system, which connects directly to the MySugr app and offers real time glucose level data, was introduced by F Hoffmann La Roche Ltd. To satisfy the consumer demand in the European market, Ascensia Diabetes Care Holdings AG acquired Senseonics Inc.’s distribution of EVERSENSE XL in February 2021 in Germany, Italy, Switzerland, Poland, Netherlands, and Spain. Market Leaders Produce a Variety of Devices, Including: Name Feature Key Player The Eclipse 3 Sensor Features: - Long Term Bluetooth Connectivity Use of Low energy Implantable Sensor Clinical Accuracy Differential Measurement Continental Carbon Company Eversense CGM System Feature: - Discreet Alert Glucose Monitoring Patch Long-Term Convenience Peace of mind and accuracy Gentle on skin Accurate Reading Senseonics Holdings, Inc. GlucoMen Day CGM Feature: - Glucose Monitoring Patch Long-Term Convenience Peace of mind and accuracy Gentle on skin A. Menarini Diagnostics Frequently Asked Question About This Report What are the key factors driving the market? Several reasons primarily cause the rising prevalence of diabetes, including rapid urbanization and the rising trend toward a sedentary lifestyle in emerging and developed nations. Moreover, the prevalence of type-1 or insulin-dependent Type-2 diabetic patients has also significantly increased, which has contributed to the rapid global adoption of these systems. How big is the continuous glucose monitoring market? The global continuous glucose monitoring market size was $6.13 billion in 2021 and is expected to reach a value of $16.33 billion by 2030. What is the continuous glucose monitoring market growth? The global continuous glucose monitoring market is expected to grow at a compound annual growth rate (CAGR) of 11.5% from 2021 to 2030 to reach USD 16.33 billion by 2030. Which market sector held the biggest share of continuous glucose monitoring devices? The highest market share for continuous glucose monitoring devices is attributable to the component segment. Sources https://abbott.mediaroom.com/2021-09-28-Real-World-Data-Show-Abbotts-FreeStyle-LibreLink-App-Users-Spend-More-Time-in-Target-Glucose-Range-Compared-to-Reader-Users https://diabetesatlas.org/data/en/world/ https://pubmed.ncbi.nlm.nih.gov/26908931/ https://main.icmr.nic.in/sites/default/files/upload_documents/ICMR_Guidelines_for_Management_of_Type_1_Diabetes.pdf 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Continuous Glucose Monitoring Devices Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Continuous Glucose Monitoring Devices Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 market, By Product, 2021 - 2030 (USD Million) 4.5 By Application Business Analysis 4.5.1 market, By Application, 2021 - 2030 (USD Million) 4.6 Component Business Analysis 4.6.1 market, By Component, 2021 - 2030 (USD Million) 4.7 End-user Business Analysis 4.7.1 market, By End-user, 2021 - 2030 (USD Million) 4.8 Demographics Analysis 4.8.1 market, By Demographics, 2021 - 2030 (USD Million) 4.9 Testing Site Analysis 4.9.1 market, By Testing Site, 2021 - 2030 (USD Million) 4.10 Value Chain Analysis 4.11 Market Variable Analysis 4.11.1 Market Drivers Analysis 4.11.2 Market Restraints Analysis 4.12 Business Environment Analysis Tool 4.12.1 market PEST analysis 4.12.2 market Porter’s analysis 4.13 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-user Analysis 5.11.1. Trends in End-user (2014-2021) 5.11.2. Trends in End-user (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. SMBG Systems (Testing Strips, Blood Glucose Meters, Lancets) 7.3.1. SMBG Systems (Testing Strips, Blood Glucose Meters, Lancets) market, 2021 - 2030 (USD Million) 7.4. CBM Systems (Transmitters, Services, Receiver) 7.4.1. CBM Systems (Transmitters, Services, Receiver) market, 2021 - 2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Gestational Diabetes 8.3.1. Gestational Diabetes market, 2021 - 2030 (USD Million) 8.4. Type 2 Diabetes 8.4.1. Type 2 Diabetes market, 2021 - 2030 (USD Million) 8.5. Type 1 Diabetes 8.5.1. Type 1 Diabetes market, 2021 - 2030 (USD Million) 9. Market: By Component Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Integrated Insulin Pumps 9.3.1. Integrated Insulin Pumps market, 2021 - 2030 (USD Million) 9.4. Services 9.4.1. Services market, 2021 - 2030 (USD Million) 9.5. Receivers 9.5.1. Receivers market, 2021 - 2030 (USD Million) 9.6. Transmitters 9.6.1. Transmitters market, 2021 - 2030 (USD Million) 10. Market: By End-user Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. ICUs 10.3.1. ICUs market, 2021 - 2030 (USD Million) 10.4. Diagnostics/Clinics 10.4.1. Diagnostics/Clinics market, 2021 - 2030 (USD Million) 10.5. Home Healthcare 10.5.1. Home Healthcare market, 2021 - 2030 (USD Million) 11. Market: By Demographics Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Child Population (≤14 years) 11.3.1. Child Population (≤14 years) market, 2021 - 2030 (USD Million) 11.4. Adult population (>14 years) 11.4.1. Adult population (>14 years) market, 2021 - 2030 (USD Million) 12. Market: By Testing Site Segment Analysis 12.1. Introduction 12.2. Sales Volume & Revenue Analysis (2021-2030) 12.3. Alternate Site Testing 12.3.1. Alternate Site Testing market, 2021 - 2030 (USD Million) 12.4. Fingertip Testing 12.4.1. Fingertip Testing market, 2021 - 2030 (USD Million) 13. Market: Regional Outlook 13.1 North America 13.1.1. North America market, By Product, 2021 - 2030 (USD Million) 13.1.2. North America market, By Application, 2021 - 2030 (USD Million) 13.1.3. North America market, by End-user, 2021 - 2030 (USD Million) 13.1.4. North America market, by Testing Site, 2021 - 2030 (USD Million) 13.1.5. North America market, by Demographics, 2021 - 2030 (USD Million) 13.1.6. North America market, by Country, 2021 - 2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By Product, 2021 - 2030 (USD Million) 12.1.4.1.2. U.S. market, By Application, 2021 - 2030 (USD Million) 12.1.4.1.3. U.S. market, by End-user, 2021 - 2030 (USD Million) 12.1.4.1.4. U.S. market, by Testing Site, 2021 - 2030 (USD Million) 12.1.4.1.5. U.S. market, by Demographics, 2021 - 2030 (USD Million) 12.1.4.1.6. U.S. market, by Country, 2021 - 2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By Product, 2021 - 2030 (USD Million) 12.1.4.2.2. Canada market, By Application, 2021 - 2030 (USD Million) 12.1.4.2.3. Canada market, by End-user, 2021 - 2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By Product, 2021 - 2030 (USD Million) 12.2.2. Europe market, By Application, 2021 - 2030 (USD Million) 12.2.3. Europe market, by End-user, 2021 - 2030 (USD Million) 12.2.4. Europe market, by Testing Site, 2021 - 2030 (USD Million) 12.2.5. Europe market, by Demographics, 2021 - 2030 (USD Million) 12.2.6. Europe market, by country, 2021 - 2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By Product, 2021 - 2030 (USD Million) 12.2.4.1.2. U.K. market, By Application, 2021 - 2030 (USD Million) 12.2.4.1.3. U.K. market, by End-user, 2021 - 2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By Product, 2021 - 2030 (USD Million) 12.2.4.2.2. Germany market, By Application, 2021 - 2030 (USD Million) 12.2.4.2.3. Germany market, by End-user, 2021 - 2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By Product, 2021 - 2030 (USD Million) 12.2.4.3.2. France market, By Application, 2021 - 2030 (USD Million) 12.2.4.3.3. France market, by End-user, 2021 - 2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By Product, 2021 - 2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Application, 2021 - 2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by End-user, 2021 - 2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By Product, 2021 - 2030 (USD Million) 12.3.2. Asia Pacific market, By Application, 2021 - 2030 (USD Million) 12.3.3. Asia Pacific market, by End-user, 2021 - 2030 (USD Million) 12.3.4. Asia Pacific market, by Testing Site, 2021 - 2030 (USD Million) 12.3.5. Asia Pacific market, by Demographics, 2021 - 2030 (USD Million) 12.3.6. Asia Pacific market, by country, 2021 - 2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By Product, 2021 - 2030 (USD Million) 12.3.4.1.2. China market, By Application, 2021 - 2030 (USD Million) 12.3.4.1.3. China market, by End-user, 2021 - 2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By Product, 2021 - 2030 (USD Million) 12.3.4.2.2. India market, By Application, 2021 - 2030 (USD Million) 12.3.4.2.3. India market, by End-user, 2021 - 2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By Product, 2021 - 2030 (USD Million) 12.3.4.3.2. Japan market, By Application, 2021 - 2030 (USD Million) 12.3.4.3.3. Japan market, by End-user, 2021 - 2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By Product, 2021 - 2030 (USD Million) 12.3.4.4.2. South Korea market, By Application, 2021 - 2030 (USD Million) 12.3.4.4.3. South Korea market, by End-user, 2021 - 2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By Product, 2021 - 2030 (USD Million) 12.3.4.5.2. Rest of ASIA PACIFIC market, By Application, 2021 - 2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021 - 2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By Product, 2021 - 2030 (USD Million) 12.4.2. Latin America market, By Application, 2021 - 2030 (USD Million) 12.4.3. Latin America market, by End-user, 2021 - 2030 (USD Million) 12.4.4. Latin America market, by Testing Site, 2021 - 2030 (USD Million) 12.4.5. Latin America market, by Demographics, 2021 - 2030 (USD Million) 12.4.6. Latin America market, by Component, 2021 - 2030 (USD Million) 12.4.7. Latin America market, by country, 2021 - 2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By Product, 2021 - 2030 (USD Million) 12.4.4.1.2. Brazil market, By Application, 2021 - 2030 (USD Million) 12.4.4.1.3. Brazil market, by End-user, 2021 - 2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By Product, 2021 - 2030 (USD Million) 12.4.4.2.2. Mexico market, By Application, 2021 - 2030 (USD Million) 12.4.4.2.3. Mexico market, by End-user, 2021 - 2030 (USD Million) 12.4.4.3. Rest of Latin America 12.4.4.3.1. Rest of the Latin America market, By Product, 2021 - 2030 (USD Million) 12.4.4.3.2. Rest of the Latin America market, By Application, 2021 - 2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by End-user, 2021 - 2030 (USD Million) 12.5. MEA 12.5.1. MEA market, By Product, 2021 - 2030 (USD Million) 12.5.2. MEA market, By Application, 2021 - 2030 (USD Million) 12.5.3. MEA market, by End-user, 2021 - 2030 (USD Million) 12.5.4. MEA market, by Component, 2021 - 2030 (USD Million) 12.5.4. MEA market, by Testing Site, 2021 - 2030 (USD Million) 12.5.4. MEA market, by region, 2021 - 2030 (USD Million) 13. Competitive Landscape 13.1 GlySens Incorporated 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Product Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. Abbott Laboratories 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Product Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. F. HOFFMANN-LA ROCHE LTD. 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Product Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. Dexcom, Inc. 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Product Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. Senseonics Holdings, Inc. 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Product Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. A. Menarini Diagnostics 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Product Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. LifeScan IP Holdings LLC 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Product Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Medtronic plc 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Product Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. ECHO THERAPEUTICS, INC. 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Product Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. Johnson & Johnson 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Product Portfolio Analysis 13.10.4. Business Strategy & Recent Development 13.11. B Braun Melsungen A 13.11.1. Company overview 13.11.2. Financial performance 13.11.3. Product Portfolio Analysis 13.11.4. Business Strategy & Recent Development 13.12. Terumo Corporation 13.12.1. Company overview 13.12.2. Financial performance 13.12.3. Product Portfolio Analysis 13.12.4. Business Strategy & Recent Development List of Tables (70 Tables) TABLE 1. MARKET, By Product, 2021-2030 (USD Million) TABLE 2. MARKET FOR SMBG Systems (Testing Strips, Blood Glucose Meters, Lancets), BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR CBM Systems (Transmitters, Services, Receiver), BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET, By Application, 2021-2030 (USD Million) TABLE 5. MARKET FOR Gestational Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Type 2 Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Type 1 Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 9. MARKET FOR ICUs, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Diagnostics/Clinics, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET FOR Home Healthcare, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET, By Component, 2021-2030 (USD Million) TABLE 13. MARKET FOR Integrated Insulin Pumps, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Services, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET, By Demographics, 2021-2030 (USD Million) TABLE 16. MARKET FOR Child Population (≤14 years), BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Health Tracking & Insights, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET FOR Adult population (>14 years), BY REGION, 2021-2030 (USD Million) TABLE 19. MARKET, By Testing Site, 2021-2030 (USD Million) TABLE 20. MARKET FOR Alternate Site Testing, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Fingertip Testing, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 23. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. NORTH AMERICA MARKET, By Product, 2021-2030 (USD Million) TABLE 25. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million) TABLE 26. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 27. NORTH AMERICA MARKET, BY Testing Site, 2021-2030 (USD Million) TABLE 28. NORTH AMERICA MARKET, BY Demographics, 2021-2030 (USD Million) TABLE 29. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 30. EUROPE MARKET, By Product, 2021-2030 (USD Million) TABLE 31. EUROPE MARKET, By Application, 2021-2030 (USD Million) TABLE 32. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 33. EUROPE MARKET, BY Testing Site, 2021-2030 (USD Million) TABLE 34. EUROPE MARKET, BY Demographics, 2021-2030 (USD Million) TABLE 35. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 36. ASIA-PACIFIC MARKET, By Product, 2021-2030 (USD Million) TABLE 37. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million) TABLE 38. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 39. ASIA-PACIFIC MARKET, BY Testing Site, 2021-2030 (USD Million) TABLE 40. ASIA-PACIFIC MARKET, BY Demographics, 2021-2030 (USD Million) TABLE 41. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 42. LAMEA MARKET, By Product, 2021-2030 (USD Million) TABLE 43. LAMEA MARKET, By Component, 2021-2030 (USD Million) TABLE 44. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 45. LAMEA MARKET, BY Testing Site, 2021-2030 (USD Million) TABLE 46. LAMEA MARKET, BY Demographics, 2021-2030 (USD Million) TABLE 47. GlySens Incorporated: COMPANY SNAPSHOT TABLE 48. GlySens Incorporated: OPERATING SEGMENTS TABLE 49. Abbott Laboratories: COMPANY SNAPSHOT TABLE 50. Abbott Laboratories: OPERATING SEGMENTS TABLE 51. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT TABLE 52. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS TABLE 53. Dexcom, Inc.: COMPANY SNAPSHOT TABLE 54. Dexcom, Inc.: OPERATING SEGMENTS TABLE 55. Senseonics Holdings, Inc.: COMPANY SNAPSHOT TABLE 56. Senseonics Holdings, Inc.: OPERATING SEGMENTS TABLE 57. A. Menarini Diagnostics: COMPANY SNAPSHOT TABLE 58. A. Menarini Diagnostics: OPERATING SEGMENTS TABLE 59. LifeScan IP Holdings LLC: COMPANY SNAPSHOT TABLE 60. LifeScan IP Holdings LLC: OPERATING SEGMENTS TABLE 61. Medtronic plc: COMPANY SNAPSHOT TABLE 62. Medtronic plc: OPERATING SEGMENTS TABLE 63. ECHO THERAPEUTICS, INC.: COMPANY SNAPSHOT TABLE 64. ECHO THERAPEUTICS, INC.: OPERATING SEGMENTS TABLE 65. Johnson & Johnson: COMPANY SNAPSHOT TABLE 66. Johnson & Johnson: OPERATING SEGMENTS TABLE 67. B Braun Melsungen A: COMPANY SNAPSHOT TABLE 68. B Braun Melsungen A: OPERATING SEGMENTS TABLE 69. Terumo Corporation: COMPANY SNAPSHOT TABLE 70. Terumo Corporation: OPERATING SEGMENTS List of Figures (26 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 12 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Continuous Glucose Monitoring Market, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Continuous Glucose Monitoring Market, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Demographics, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Component, 2019 vs. 2025 (USD Million) Figure 16 Market Share, By Testing Site, 2019 vs. 2025 (USD Million) Figure 17 Geographical Snapshot of the Market Figure 18 Home Healthcare to Witness Higher CAGR in Market for End-user Segment during Forecast Period. Figure 19 Sensors to Witness Higher CAGR in Market for Component Segment during Forecast Period. Figure 20 Adult population (>14 years) to Witness Higher CAGR in Market for Demographics Segment during Forecast Period. Figure 21 Type 2 Diabetes to Witness Higher CAGR in the Market for Application Segment during Forecast Period. Figure 22 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 23 Market: Drivers, Restraints, Opportunities, and Challenges Figure 24 North America: Market Snapshot Figure 25 Asia Pacific: Market Snapshot Figure 26 Vendor Dive: Evaluation Overview